Effectiveness of the adapted bivalent mRNA COVID-19 vaccines
against hospitalisation in individuals aged ≥ 60 years during
the Omicron XBB lineage-predominant period: VEBIS SARI VE
network, Europe, February to August, 2023

J 2024

Effectiveness of the adapted bivalent mRNA COVID-19 vaccines against hospitalisation in individuals aged ≥ 60 years during the Omicron XBB lineage-predominant period: VEBIS SARI VE network, Europe, February to August, 2023

ANTUNES, Liliana, Clara MAZAGATOS, Iván MARTÍNEZ-BAZ, Verónica GOMEZ, Borg MARIA-LOUISE et. al.

Základní údaje

Originální název

Effectiveness of the adapted bivalent mRNA COVID-19 vaccines against hospitalisation in individuals aged ≥ 60 years during the Omicron XBB lineage-predominant period: VEBIS SARI VE network, Europe, February to August, 2023

Autoři

Vydání

EUROSURVEILLANCE, STOCKHOLM, EUR CENTRE DIS PREVENTION & CONTROL, 2024, 1025-496X

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30303 Infectious Diseases

Stát vydavatele

Švédsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 19.000 v roce 2022

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.2807/1560-7917.ES.2024.29.3.2300708

UT WoS

001199954400004

Klíčová slova anglicky

bivalent mRNA COVID-19 vaccines;Omicron XBB lineage-predominant period;VEBIS SARI VE network

Štítky

14110214

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 21. 8. 2024 11:43, Mgr. Tereza Miškechová

Anotace

V originále

We conducted a multicentre hospital-based test-negative case–control study to measure the effectiveness of adapted bivalent COVID-19 mRNA vaccines against PCR-confirmed SARS-CoV-2 infection during the Omicron XBB lineage-predominant period in patients aged ≥ 60 years with severe acute respiratory infection from five countries in Europe. Bivalent vaccines provided short-term additional protection compared with those vaccinated > 6 months before the campaign: from 80% (95% CI: 50 to 94) for 14–89 days post-vaccination, 15% (95% CI: −12 to 35) at 90–179 days, and lower to no effect thereafter.

Návaznosti

90249, velká výzkumná infrastruktura

Název: CZECRIN IV

Citovat

ANTUNES, Liliana, Clara MAZAGATOS, Iván MARTÍNEZ-BAZ, Verónica GOMEZ, Borg MARIA-LOUISE, Goranka PETROVIĆ, Róisín DUFFY, François E DUFRASNE, Ralf DÜRRWALD, Mihaela LAZAR, Ligita JANCORIENE, Beatrix OROSZI, Petr HUSA, Jennifer HOWARD, Aryse MELO, Francisco POZO, Gloria PÉREZ-GIMENO, Jesús CASTILLA, Ausenda MACHADO, Aušra DŽIUGYTĖ, Svjetlana KARABUVA, Margaret FITZGERALD, Sébastien FIERENS, Kristin TOLKSDORF, Popovici SILVIA-ODETTE, Auksė MICKIENĖ, Gergő TÚRI, Lenka SOUČKOVÁ, Nathalie NICOLAY a Angela Mc ROSE. Effectiveness of the adapted bivalent mRNA COVID-19 vaccines against hospitalisation in individuals aged ≥ 60 years during the Omicron XBB lineage-predominant period: VEBIS SARI VE network, Europe, February to August, 2023. EUROSURVEILLANCE. STOCKHOLM: EUR CENTRE DIS PREVENTION & CONTROL, 2024, roč. 29, č. 3, s. 1-8. ISSN 1025-496X. Dostupné z: https://dx.doi.org/10.2807/1560-7917.ES.2024.29.3.2300708.

@article{2364017,
   author = {Antunes, Liliana and Mazagatos, Clara and MartínezandBaz, Iván and Gomez, Verónica and MariaandLouise, Borg and Petrović, Goranka and Duffy, Róisín and Dufrasne, François E and Dürrwald, Ralf and Lazar, Mihaela and Jancoriene, Ligita and Oroszi, Beatrix and Husa, Petr and Howard, Jennifer and Melo, Aryse and Pozo, Francisco and PérezandGimeno, Gloria and Castilla, Jesús and Machado, Ausenda and Džiugytė, Aušra and Karabuva, Svjetlana and Fitzgerald, Margaret and Fierens, Sébastien and Tolksdorf, Kristin and SilviaandOdette, Popovici and Mickienė, Auksė and Túri, Gergő and Součková, Lenka and Nicolay, Nathalie and Rose, Angela Mc},
   article_location = {STOCKHOLM},
   article_number = {3},
   doi = {http://dx.doi.org/10.2807/1560-7917.ES.2024.29.3.2300708},
   keywords = {bivalent mRNA COVID-19 vaccines;Omicron XBB lineage-predominant period;VEBIS SARI VE network},
   language = {eng},
   issn = {1025-496X},
   journal = {EUROSURVEILLANCE},
   title = {Effectiveness of the adapted bivalent mRNA COVID-19 vaccines against hospitalisation in individuals aged ≥ 60 years during the Omicron XBB lineage-predominant period: VEBIS SARI VE network, Europe, February to August, 2023},
   url = {https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2024.29.3.2300708#abstract_content},
   volume = {29},
   year = {2024}
}

TY  - JOUR
ID  - 2364017
AU  - Antunes, Liliana - Mazagatos, Clara - Martínez-Baz, Iván - Gomez, Verónica - Maria-Louise, Borg - Petrović, Goranka - Duffy, Róisín - Dufrasne, François E - Dürrwald, Ralf - Lazar, Mihaela - Jancoriene, Ligita - Oroszi, Beatrix - Husa, Petr - Howard, Jennifer - Melo, Aryse - Pozo, Francisco - Pérez-Gimeno, Gloria - Castilla, Jesús - Machado, Ausenda - Džiugytė, Aušra - Karabuva, Svjetlana - Fitzgerald, Margaret - Fierens, Sébastien - Tolksdorf, Kristin - Silvia-Odette, Popovici - Mickienė, Auksė - Túri, Gergő - Součková, Lenka - Nicolay, Nathalie - Rose, Angela Mc
PY  - 2024
TI  - Effectiveness of the adapted bivalent mRNA COVID-19 vaccines against hospitalisation in individuals aged ≥ 60 years during the Omicron XBB lineage-predominant period: VEBIS SARI VE network, Europe, February to August, 2023
JF  - EUROSURVEILLANCE
VL  - 29
IS  - 3
SP  - 1-8
EP  - 1-8
PB  - EUR CENTRE DIS PREVENTION & CONTROL
SN  - 1025496X
KW  - bivalent mRNA COVID-19 vaccines;Omicron XBB lineage-predominant period;VEBIS SARI VE network
UR  - https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2024.29.3.2300708#abstract_content
N2  - We conducted a multicentre hospital-based test-negative case–control study to measure the effectiveness of adapted bivalent COVID-19 mRNA vaccines against PCR-confirmed SARS-CoV-2 infection during the Omicron XBB lineage-predominant period in patients aged ≥ 60 years with severe acute respiratory infection from five countries in Europe. Bivalent vaccines provided short-term additional protection compared with those vaccinated > 6 months before the campaign: from 80% (95% CI: 50 to 94) for 14–89 days post-vaccination, 15% (95% CI: −12 to 35) at 90–179 days, and lower to no effect thereafter.
ER  -

ANTUNES, Liliana, Clara MAZAGATOS, Iván MARTÍNEZ-BAZ, Verónica GOMEZ, Borg MARIA-LOUISE, Goranka PETROVI$\backslash$'C, Róisín DUFFY, Fran$\backslash$c cois E DUFRASNE, Ralf DÜRRWALD, Mihaela LAZAR, Ligita JANCORIENE, Beatrix OROSZI, Petr HUSA, Jennifer HOWARD, Aryse MELO, Francisco POZO, Gloria PÉREZ-GIMENO, Jesús CASTILLA, Ausenda MACHADO, Aušra DŽIUGYTĖ, Svjetlana KARABUVA, Margaret FITZGERALD, Sébastien FIERENS, Kristin TOLKSDORF, Popovici SILVIA-ODETTE, Auksė MICKIENĖ, Gerg$\backslash$H o TÚRI, Lenka SOUČKOVÁ, Nathalie NICOLAY a Angela Mc ROSE. Effectiveness of the adapted bivalent mRNA COVID-19 vaccines against hospitalisation in individuals aged ≥ 60 years during the Omicron XBB lineage-predominant period: VEBIS SARI VE network, Europe, February to August, 2023. \textit{EUROSURVEILLANCE}. STOCKHOLM: EUR CENTRE DIS PREVENTION \&{} CONTROL, 2024, roč.~29, č.~3, s.~1-8. ISSN~1025-496X. Dostupné z: https://dx.doi.org/10.2807/1560-7917.ES.2024.29.3.2300708.

Podrobný výpis o publikaci